On June 25, 2019, Mrs. Xiaopeng Li, a member of the Board of Directors of Oramed Pharmaceuticals Inc., notified the company of her intention to resign from the Board for personal reasons, effective immediately. Mrs. Xiaopeng Li did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices. On July 1, 2019, the Board appointed Mr. Xiaoming Gao as a member of the Board to fill the vacancy resulting from Mrs. Li’s resignation. Mr. Xiaoming Gao was not, and is not expected to be, appointed to serve on any Board committees. Mr. Xiaoming Gao is the chairman of Technology License Agreement with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and has more than 30 years of experience in the insulin industry and was responsible for introducing Novo Nordisk insulin to China. In 2007, he founded Hefei Tianmai Biotechnology development Co. Ltd. ("HTBT") and started recombinant human insulin and insulin analogs’ R&D manufacturing for the Greater China region.